Rapamycin Improved Brain Blood Flow in APOE4 Carriers

In a four-week pilot trial, healthy adults aged 45–65 carrying the APOE4 variant who took a low daily dose of rapamycin showed improved cerebral blood flow, with the largest gains in women. The study was published in the Journal of Cerebral Blood Flow & Metabolism.

• Participants aged 45–65 took a low daily dose of rapamycin for four weeks
• Brain blood flow improved only in APOE4 carriers
• The greatest improvement was seen in women with APOE4
• The trial does not establish long-term memory protection